Axsome Therapeutics, Inc. (AXSM) vs ImmunityBio, Inc. (IBRX)
Axsome Therapeutics, Inc. and ImmunityBio, Inc. are both Biotechnology companies. Axsome Therapeutics, Inc. is the larger, with a market value of $10.3B against $9.2B — 1.1× the size. ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 56.9%. Axsome Therapeutics, Inc. has the higher net margin (−24.7% vs −598.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Axsome Therapeutics, Inc. leads on 8 and ImmunityBio, Inc. on 7.
Valuation
Profitability
| Metric | AXSM | IBRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 93.24% | 99.34% | 65.16% |
| Operating margin | (23.96%) | (151.88%) | 0.00% |
| Net margin | (24.68%) | (598.56%) | 0.00% |
| Free cash flow margin | (9.27%) | (173.76%) | 0.00% |
| Return on equity | (245.10%) | 122.85% | (57.72%) |
| Return on assets | (27.35%) | (192.58%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack